GlaxoSmithKline Acquires CMG1A46 for $300 Million

Glaxosmithkline (GSK), a leading global pharmaceutical company, has formally agreed to acquire CMG1A46 developed by Chimagen Biosciences for an upfront consideration of US $300 million. CMG1A46 is a therapy in clinical stages designed to treat autoimmune diseases driven by B cells. This therapy is unique in that it targets CD19 and CD20 molecules, acting through a T-cell engager mechanism.

This acquisition further demonstrates GSK's strong commitment to the treatment of autoimmune diseases. The company has been working to develop therapies for diseases such as lupus nephritis and systemic lupus erythematosus, and the acquisition of CMG1A46 has the potential to expand the treatment to other related autoimmune diseases. GSK will receive full global rights to the therapy, meaning the company will have the exclusive right to develop and commercialize CMG1A46 worldwide.

Under the agreement reached between the parties, Chimagen Biosciences will also be eligible for up to $550 million in potential milestone payments that will be based on the successful development and commercial rollout of CMG1A46. In addition, the agreement between the two companies is subject to a number of customary conditions, including the receipt of regulatory licenses under the U.S. Hart-Scott-Rodino Act.

Tony Wood, chief scientific Officer at GSK, said: "Through our work in systemic lupus erythematosus and lupus nephritis, we have gained a deeper understanding of the underlying drivers of B-cell-driven disease. CMG1A46 offers exciting potential as a novel treatment option targeting deep B-cell depletion. We are excited to move forward to address the unmet need in lupus and related autoimmune diseases."

This acquisition of CMG1A46 is a strategic move to address the diverse manifestations of lupus and the ongoing burden it places on patients, particularly those with severe disease who do not respond to current therapies. As a targeted therapy in the treatment of autoimmune diseases, emerging clinical evidence suggests that CD20 may offer a different therapeutic approach due to its presence in a wider range of B cell types.

Zhenhao Zhou, Chief Executive Officer of Chimagen Biosciences, said, "We are excited about the potential of CMG1A46 to improve the lives of patients with autoimmune diseases and thank GSK for accelerating the realization of this vision. This agreement provides further validation for our proprietary T-cell engager platform, and we are eager to continue our mission of developing novel multispecific antibody therapies."

In preclinical studies, CMG1A46 has shown rapid and profound B-cell depletion in both blood and tissue, which could lead to a more sustained patient response. The treatment is currently in phase I clinical trials in the United States and China for lymphoma and leukemia. GSK plans to initiate a Phase 1 trial in lupus in 2025 to further validate the efficacy and safety of CMG1A46.